| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1024843331 |
| P356 | DOI | 10.1038/NRD1063 |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1038/nrd1063 |
| P698 | PubMed publication ID | 12669025 |
| P2093 | author name string | Mark Namchuk | |
| W Patrick Walters | |||
| P2860 | cites work | Principles and biophysical applications of lanthanide-based probes | Q34623600 |
| Fluorescence imaging and engineered biosensors: functional and activity-based sensing using high content screening | Q34704077 | ||
| Chemogenomics: bridging a drug discovery gap. | Q35018904 | ||
| Why do we need so many chemical similarity search methods? | Q35053182 | ||
| Chemical similarity searches using latent semantic structural indexing (LaSSI) and comparison to TOPOSIM. | Q38440752 | ||
| A single amino acid substitution makes ERK2 susceptible to pyridinyl imidazole inhibitors of p38 MAP kinase | Q42029877 | ||
| Property-based design of GPCR-targeted library | Q44165334 | ||
| Consensus scoring: A method for obtaining improved hit rates from docking databases of three-dimensional structures into proteins. | Q52132563 | ||
| A scoring scheme for discriminating between drugs and nondrugs. | Q52237197 | ||
| Small Molecule Docking and Scoring | Q56210380 | ||
| Current trends in lead discovery: are we looking for the appropriate properties? | Q57017035 | ||
| A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases | Q28140411 | ||
| A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays | Q28145712 | ||
| Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings | Q28842973 | ||
| Finding the molecules to fuel chemogenomics | Q29543531 | ||
| Drug-like properties and the causes of poor solubility and poor permeability | Q30660926 | ||
| Recognizing molecules with drug-like properties | Q30741925 | ||
| Molecular scaffold-based design and comparison of combinatorial libraries focused on the ATP-binding site of protein kinases | Q30836871 | ||
| Property distribution of drug-related chemical databases. | Q30855791 | ||
| High throughput docking for library design and library prioritization | Q30984706 | ||
| Simple selection criteria for drug-like chemical matter | Q30990966 | ||
| Molecular complexity and its impact on the probability of finding leads for drug discovery | Q30993107 | ||
| Virtual screening of combinatorial libraries across a gene family: in search of inhibitors of Giardia lamblia guanine phosphoribosyltransferase | Q31001616 | ||
| Can we learn to distinguish between "drug-like" and "nondrug-like" molecules? | Q32032942 | ||
| Computational methods to predict binding free energy in ligand-receptor complexes | Q34369739 | ||
| Discovery of cytokine mimics using cell-based systems | Q34374649 | ||
| Prediction of intestinal permeability | Q34581541 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 259-266 | |
| P577 | publication date | 2003-04-01 | |
| P1433 | published in | Nature Reviews Drug Discovery | Q45998 |
| P1476 | title | Designing screens: how to make your hits a hit. | |
| P478 | volume | 2 |
| Q36329722 | A Fluorescence-based Lymphocyte Assay Suitable for High-throughput Screening of Small Molecules |
| Q33712791 | A Method for Identifying Small-Molecule Aggregators Using Photonic Crystal Biosensor Microplates |
| Q33229805 | A chemoinformatics analysis of hit lists obtained from high-throughput affinity-selection screening |
| Q43068223 | A comparative study on the molecular descriptors for predicting drug-likeness of small molecules |
| Q42007896 | A detergent-based assay for the detection of promiscuous inhibitors |
| Q30527857 | A focused small-molecule screen identifies 14 compounds with distinct effects on Toxoplasma gondii |
| Q57591357 | A new model for utilising chemical diversity from natural sources |
| Q36189485 | A one-pot-three-step route to triazolotriazepinoindazolones from oxazolino-2H-indazoles |
| Q30844551 | A staged screening of registered drugs highlights remyelinating drug candidates for clinical trials |
| Q91666988 | ADMET-score - a comprehensive scoring function for evaluation of chemical drug-likeness |
| Q41897294 | Acyl chloride-modified amorphous carbon substrates for the attachment of alcohol-, thiol-, and amine-containing molecules |
| Q33263840 | Adenoviral sensors for high-content cellular analysis |
| Q38866173 | An Overview of Current Approaches Toward the Treatment and Prevention of West Nile Virus Infection |
| Q33257634 | An ultraefficient affinity-based high-throughout screening process: application to bacterial cell wall biosynthesis enzyme MurF. |
| Q41269662 | Antibiotic-inducible promoter regulated by the cell envelope stress-sensing two-component system LiaRS of Bacillus subtilis |
| Q47153340 | Assay interference and off-target liabilities of reported histone acetyltransferase inhibitors |
| Q86376331 | Ayurvedic drug discovery |
| Q28550778 | Bilayer Effects of Antimalarial Compounds |
| Q33404831 | Characterization and optimization of a red-shifted fluorescence polarization ADP detection assay |
| Q26779035 | Charting a Path to Success in Virtual Screening |
| Q28260664 | Chemogenomics: an emerging strategy for rapid target and drug discovery |
| Q39189071 | Colloidal aggregation causes inhibition of G protein-coupled receptors |
| Q27662173 | Complementarity Between a Docking and a High-Throughput Screen in Discovering New Cruzain Inhibitors |
| Q27650049 | Comprehensive Mechanistic Analysis of Hits from High-Throughput and Docking Screens against β-Lactamase |
| Q93112180 | Computational advances in combating colloidal aggregation in drug discovery |
| Q38819860 | Computer-aided discovery of new FGFR-1 inhibitors followed by in vitro validation. |
| Q31139520 | Data-driven approaches used for compound library design, hit triage and bioactivity modeling in high-throughput screening |
| Q47278992 | Determining appropriate substrate conversion for enzymatic assays in high-throughput screening |
| Q33371987 | Developing and validating predictive decision tree models from mining chemical structural fingerprints and high-throughput screening data in PubChem |
| Q47360713 | Development of a BRET2 screening assay using beta-arrestin 2 mutants |
| Q38088731 | Discovery and development of melanin-concentrating hormone receptor 1 antagonists for the treatment of obesity |
| Q48236350 | Discovery of Key Physicochemical, Structural, and Spatial Properties of RNA-Targeted Bioactive Ligands. |
| Q38777885 | Discovery of Novel Tricyclic Thiazepine Derivatives as Anti-Drug-Resistant Cancer Agents by Combining Diversity-Oriented Synthesis and Converging Screening Approach |
| Q35135050 | Discovery of a novel inhibitor of NAD(P)(+)-dependent malic enzyme (ME2) by high-throughput screening |
| Q31152254 | Diversifying carotenoid biosynthetic pathways by directed evolution |
| Q33231454 | Diversity-oriented synthesis: exploring the intersections between chemistry and biology |
| Q30489011 | Docking Screens for Novel Ligands Conferring New Biology |
| Q36513179 | Drug-likeness analysis of traditional Chinese medicines: 1. property distributions of drug-like compounds, non-drug-like compounds and natural compounds from traditional Chinese medicines |
| Q50744649 | Elaborate ligand-based modeling coupled with QSAR analysis and in silico screening reveal new potent acetylcholinesterase inhibitors. |
| Q30405622 | Enhancing reproducibility in cancer drug screening: how do we move forward? |
| Q33890527 | Estimation of affinities of ligands in mixtures via magnetic recovery of target-ligand complexes and chromatographic analyses: chemometrics and an experimental model |
| Q53076714 | Exploring G Protein-Coupled Receptors (GPCRs) Ligand Space via Cheminformatics Approaches: Impact on Rational Drug Design. |
| Q34407592 | Exploring the potential of endophytes from medicinal plants as sources of antimycobacterial compounds |
| Q41467248 | Fluorescence polarization assays in high-throughput screening and drug discovery: a review |
| Q58856163 | Focus on PAINS: false friends in the quest for selective anti-protozoal lead structures from Nature? |
| Q30278790 | HCS campaign to identify selective inhibitors of IL-6-induced STAT3 pathway activation in head and neck cancer cell lines |
| Q38449116 | High-throughput determination of mode of inhibition in lead identification and optimization |
| Q50070054 | High-throughput screening for antimicrobial compounds using a 96-well format bacterial motility absorbance assay. |
| Q31150791 | High-throughput screening for kinase inhibitors |
| Q33601624 | High-throughput virtual screening using quantum mechanical probes: discovery of selective kinase inhibitors |
| Q27000720 | Hit identification and optimization in virtual screening: practical recommendations based on a critical literature analysis |
| Q55261330 | Homogeneous Assay for Target Engagement Utilizing Bioluminescent Thermal Shift. |
| Q46595554 | Homogeneous time-resolved fluorescence resonance energy transfer assay for measurement of Phox/Bem1p (PB1) domain heterodimerization |
| Q57385077 | Identification of Novel Keratinocyte Differentiation Modulating Compounds by High-Throughput Screening |
| Q34447440 | Improved inhibitor screening experiments by comparative analysis of simulated enzyme progress curves |
| Q56984194 | In Silico ADME/Tox Predictions |
| Q33648377 | In Vitro Selection of a DNA-Templated Small-Molecule Library Reveals a Class of Macrocyclic Kinase Inhibitors |
| Q60948280 | In vitro antiplasmodial activity, pharmacokinetic profiles and interference in isoprenoid pathway of 2-aniline-3-hydroxy-1.4-naphthoquinone derivatives |
| Q33294992 | Increasing the robustness and validity of RNAi screens |
| Q44897227 | Ion mobility-mass spectrometry applied to cyclic peptide analysis: conformational preferences of gramicidin S and linear analogs in the gas phase |
| Q41180414 | Isocyanides as Influenza A Virus Subtype H5N1 Wild-Type M2 Channel Inhibitors |
| Q28483059 | IspE inhibitors identified by a combination of in silico and in vitro high-throughput screening |
| Q92437777 | Lead optimization for promising monoamine oxidase inhibitor from eugenol for the treatment of neurological disorder: synthesis and in silico based study |
| Q33309109 | Lessons learnt from assembling screening libraries for drug discovery for neglected diseases |
| Q36342520 | Lithocholic acid is an endogenous inhibitor of MDM4 and MDM2. |
| Q35190730 | Mechanistic considerations in high-throughput screening |
| Q45943415 | Methods for Virtual Screening of GPCR Targets: Approaches and Challenges. |
| Q34552776 | Mining collections of compounds with Screening Assistant 2 |
| Q35615376 | Mining the microbial metabolome: a new frontier for natural product lead discovery |
| Q35591567 | Mitigating risk in academic preclinical drug discovery |
| Q36291814 | Molecular Modeling and Docking Study to Elucidate Novel Chikungunya Virus nsP2 Protease Inhibitors |
| Q52678127 | Molecular docking based screening of Noggin inhibitors. |
| Q47652702 | Natural product modulators of human sensations and mood: molecular mechanisms and therapeutic potential |
| Q37384418 | Non-clinical studies required for new drug development - Part I: early in silico and in vitro studies, new target discovery and validation, proof of principles and robustness of animal studies |
| Q36100771 | Novel therapeutic targets on the horizon for lung cancer. |
| Q39876040 | One-Pot Synthesis of Benzo[4,5]imidazo[2,1-a]isoquinolines and Isoquinolino[3,4-b]quinoxalines via Tandem Cyclization Strategies. |
| Q46403231 | Origins of Enzyme Catalysis: Experimental Findings for C-H Activation, New Models, and Their Relevance to Prevailing Theoretical Constructs |
| Q34460371 | PAINS in the assay: chemical mechanisms of assay interference and promiscuous enzymatic inhibition observed during a sulfhydryl-scavenging HTS. |
| Q48272301 | Pharmacological modulation of mitochondrial calcium homeostasis. |
| Q38159762 | Plant-derived food ingredients for stimulation of energy expenditure. |
| Q33435425 | Pooling in high-throughput drug screening. |
| Q35759485 | Post-HTS case report and structural alert: Promiscuous 4-aroyl-1,5-disubstituted-3-hydroxy-2H-pyrrol-2-one actives verified by ALARM NMR. |
| Q30101030 | Privileged Structures Revisited |
| Q30839726 | Quantification of frequent-hitter behavior based on historical high-throughput screening data |
| Q30883378 | Quantitative analyses of aggregation, autofluorescence, and reactivity artifacts in a screen for inhibitors of a thiol protease |
| Q37880884 | Rare actinomycetes: a potential storehouse for novel antibiotics |
| Q54246015 | Readout technologies for highly miniaturized kinase assays applicable to high-throughput screening in a 1536-well format. |
| Q36515794 | Screening in a spirit haunted world |
| Q35878687 | Selecting, Acquiring, and Using Small Molecule Libraries for High-Throughput Screening |
| Q38655350 | Simulated annealing molecular dynamics and ligand-receptor contacts analysis for pharmacophore modeling |
| Q92265740 | Stress Resistance Screen in a Human Primary Cell Line Identifies Small Molecules That Affect Aging Pathways and Extend Caenorhabditis elegans' Lifespan |
| Q35962179 | Structure-Based Virtual Screening for Dopamine D2 Receptor Ligands as Potential Antipsychotics |
| Q42594369 | Synergy and antagonism of promiscuous inhibition in multiple-compound mixtures |
| Q47935016 | Systematic Identification of MCU Modulators by Orthogonal Interspecies Chemical Screening |
| Q37557135 | Systematizing serendipity for cardiovascular drug discovery |
| Q90170351 | Tailored therapeutics based on 1,2,3-1H-triazoles: a mini review |
| Q42047280 | The Ecstasy and Agony of Assay Interference Compounds |
| Q56556602 | The Ecstasy and Agony of Assay Interference Compounds |
| Q56556620 | The Ecstasy and Agony of Assay Interference Compounds |
| Q60502259 | The Ecstasy and Agony of Assay Interference Compounds |
| Q60502262 | The Ecstasy and Agony of Assay Interference Compounds |
| Q60502263 | The Ecstasy and Agony of Assay Interference Compounds |
| Q95489016 | The Ecstasy and Agony of Assay Interference Compounds |
| Q40314472 | The Ecstasy and Agony of Assay Interference Compounds. |
| Q34432745 | The cellular thermal shift assay for evaluating drug target interactions in cells |
| Q34435458 | The essential roles of chemistry in high-throughput screening triage |
| Q35744790 | The evolution of microarrayed compound screening |
| Q28533977 | The open access malaria box: a drug discovery catalyst for neglected diseases |
| Q90291678 | The perceptions of natural compounds against dipeptidyl peptidase 4 in diabetes: from in silico to in vivo |
| Q51599141 | The quest for novel chemical matter and the contribution of computer-aided de novo design. |
| Q58616448 | Therapeutic value of steroidal alkaloids in cancer: Current trends and future perspectives |
| Q36379398 | Transcreener: screening enzymes involved in covalent regulation |
| Q36048547 | UCN-01 enhances cytotoxicity of irinotecan in colorectal cancer stem-like cells by impairing DNA damage response. |
| Q47619864 | Use of the BRET 7TM receptor/beta-arrestin assay in drug discovery and screening |
| Q30878704 | Using the BioAssay Ontology for analyzing high-throughput screening data |
| Q90193371 | Vesiculopolins, a New Class of Anti-Vesiculoviral Compounds, Inhibit Transcription Initiation of Vesiculoviruses |
| Q41588963 | Virtual-screening workflow tutorials and prospective results from the Teach-Discover-Treat competition 2014 against malaria |
| Q24288687 | When Quality Beats Quantity: Decision Theory, Drug Discovery, and the Reproducibility Crisis |
| Q35709584 | cAMP detection methods in HTS: selecting the best from the rest |
Search more.